Carlos Solorzano
Analyste en capital-investissement chez Pivotal Bioventure Partners Investment Advisor LLC
Profil
Carlos Solórzano, PhD is a Senior Principal at S32.
Carlos has more than a decade of experience in healthcare spanning academic research, investment banking, corporate strategy and BD as well as venture capital prior to joining S32.
At S32, Carlos focuses on the firm’s investment sourcing, diligence, and deal execution efforts primarily in healthcare.
Prior to S32, Carlos was a Senior Associate at Pivotal bioVenture Partners where he participated in nine investments into therapeutics companies across various stages of development and financing in various therapeutic areas.
During his tenure at Pivotal, Carlos was an observer on the board or led diligence for Akouos (NASDAQ: AKUS), Avalyn, Evommune, Plexium and Arkuda.
Carlos previously was an Associate Director in the corporate strategy and business development team at Ultragenyx Pharmaceutical where he worked on competitive intelligence, as well as portfolio, commercial and BD strategy.
In particular, Carlos participated in Ultragenyx’ option to acquire GeneTx (ASO for Angelman Syndrome), the expansion of Ultragenyx’ collaboration agreement with Arcturus Therapeutics (nucleic acid therapeutics including mRNA), as well as in the technology and portfolio strategy of Ultragenyx’ gene therapy platform.
Prior to Ultragenyx, Carlos worked as an equity research associate at Deutsche Bank and Oppenheimer & Co. covering smid- and large-cap biotech companies.
Carlos has a BS in Chemical Engineering from Cal Poly Pomona, earned a PhD in Pharmacology from UC Irvine, and was an NIH postdoctoral scholar at UC San Francisco where he investigated the neurobiology of pain and itch
Postes actifs de Carlos Solorzano
| Sociétés | Poste | Début |
|---|---|---|
Pivotal Bioventure Partners Investment Advisor LLC
 Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | Analyste en capital-investissement | 01/10/2019 |
Section 32 LLC
 Section 32 LLC Investment ManagersFinance Section 32 LLC (Section 32) is a venture capital firm founded in 2017 by Bill Maris. The firm is headquartered in Silicon Valley, California. | Private Equity Investor | - |
Anciens postes connus de Carlos Solorzano
| Sociétés | Poste | Fin |
|---|---|---|
Deutsche Bank Securities, Inc.
 Deutsche Bank Securities, Inc. Investment Banks/BrokersFinance Deutsche Bank Securities, Inc. (DBSI) is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 1971 and is a wholly-owned investment banking and brokerage arm of DB U.S. Financial Markets Holding Corp., ultimately held by Deutsche Bank AG (NYSE: DB, FRA: DBK) in Germany. DBSI provides securities brokerage and investment advisory services to domestic and international private clients and institutions. They are also a primary dealer in US government securities as designated by the Federal Reserve. | Analyst-Equity | 01/06/2018 |
Oppenheimer & Co., Inc. (Broker)
 Oppenheimer & Co., Inc. (Broker) Investment Banks/BrokersFinance Oppenheimer & Co., Inc. (Broker) (Oppenheimer-Broker) is the global full-service brokerage division of Oppenheimer & Co., Inc., an investment boutique headquartered in New York City with additional offices nationwide. Founded in 1975, the firm is owned directly by Viner Finance Inc., an indirect subsidiary of Oppenheimer Holdings Inc. (NYSE: OPY). Oppenheimer-Broker offers a full array of brokerage services to retail, institutional, and corporate clients. | Analyst-Equity | 01/08/2016 |
Advanced Cell Diagnostics, Inc.
 Advanced Cell Diagnostics, Inc. BiotechnologyHealth Technology Advanced Cell Diagnostics, Inc. operates as a biotechnology company. It specializes in the emerging field of molecular pathology and developing cell- and tissue-based diagnostic tests for personalized medicine. The company was founded by Lou Yuling and Steve Chan in 2006 and is headquartered in Newark, CA. | Corporate Officer/Principal | 01/05/2015 |
| ULTRAGENYX PHARMACEUTICAL INC. | Directeur/Membre du Conseil | - |
Formation de Carlos Solorzano
| University of California, Irvine | Doctorate Degree |
| California State Polytechnic University (Pomona) | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Oppenheimer & Co., Inc. (Broker)
Oppenheimer & Co., Inc. (Broker) Investment Banks/BrokersFinance Oppenheimer & Co., Inc. (Broker) (Oppenheimer-Broker) is the global full-service brokerage division of Oppenheimer & Co., Inc., an investment boutique headquartered in New York City with additional offices nationwide. Founded in 1975, the firm is owned directly by Viner Finance Inc., an indirect subsidiary of Oppenheimer Holdings Inc. (NYSE: OPY). Oppenheimer-Broker offers a full array of brokerage services to retail, institutional, and corporate clients. | Finance |
Advanced Cell Diagnostics, Inc.
Advanced Cell Diagnostics, Inc. BiotechnologyHealth Technology Advanced Cell Diagnostics, Inc. operates as a biotechnology company. It specializes in the emerging field of molecular pathology and developing cell- and tissue-based diagnostic tests for personalized medicine. The company was founded by Lou Yuling and Steve Chan in 2006 and is headquartered in Newark, CA. | Health Technology |
Deutsche Bank Securities, Inc.
Deutsche Bank Securities, Inc. Investment Banks/BrokersFinance Deutsche Bank Securities, Inc. (DBSI) is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 1971 and is a wholly-owned investment banking and brokerage arm of DB U.S. Financial Markets Holding Corp., ultimately held by Deutsche Bank AG (NYSE: DB, FRA: DBK) in Germany. DBSI provides securities brokerage and investment advisory services to domestic and international private clients and institutions. They are also a primary dealer in US government securities as designated by the Federal Reserve. | Finance |
Pivotal Bioventure Partners Investment Advisor LLC
Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | Finance |
Section 32 LLC
Section 32 LLC Investment ManagersFinance Section 32 LLC (Section 32) is a venture capital firm founded in 2017 by Bill Maris. The firm is headquartered in Silicon Valley, California. | Finance |